Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;6(2):101-8.

Intravitreal triamcinolone for acute branch retinal vein occlusion: a randomized clinical trial

Alireza Ramezani  1 , Morteza Entezari, Siamak Moradian, Shohreh Kadkhodaei, Homa Tabatabaei, Babak Dehsarvi, Mohammad Fatehi, Mehdi Yaseri
Affiliations

Intravitreal triamcinolone for acute branch retinal vein occlusion: a randomized clinical trial

Alireza Ramezani et al. J Ophthalmic Vis Res. 2011 Apr.

Abstract

Purpose: To evaluate the therapeutic effect of intravitreal triamcinolone (IVT) injection for recent branch retinal vein occlusion (BRVO).

Methods: In a randomized controlled clinical trial, 30 phakic eyes with recent (less than 10 weeks' duration) BRVO were assigned to two groups. The treatment group (16 eyes) received 4 mg IVT and the control group (14 eyes) received subconjunctival sham injections. Changes in visual acuity (VA) were the main outcome measure.

Results: VA and central macular thickness (CMT) changes were not significantly different between the study groups at any time point. Within group analysis showed significant VA improvement from baseline in the IVT group up to three months (P < 0.05); the amount of this change was -0.53 ± 0.46, -0.37 ± 0.50, -0.46 ± 0.50, and -0.29 ± 0.45 logMAR at 1, 2, 3, and 4 months, respectively. Corresponding VA improvements in the control group were -0.20 ± 0.37, -0.11 ± 0.46, -0.25 ± 0.58, and -0.05 ± 0.50 logMAR (all P values > 0.05). Significant reduction in CMT was noticed only in the treatment group (-172 ± 202 μm, P = 0.029) and at 4 months. Ocular hypertension occurred in 4 (25%) and 2 (14.3%) eyes in the IVT and control groups, respectively.

Conclusion: A single IVT injection had a non-significant beneficial effect on VA and CMT in acute BRVO as compared to the natural history of the condition. The 3-month deferred treatment protocol advocated by the Branch Vein Occlusion Study Group may be a safer option than IVT injection considering its potential side effects.

Keywords: Branch Retinal Vein Occlusion; Central Macular Thickness; Intraocular Pressure; Intravitreal Triamcinolone; Macular Edema; Neovascularization.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean corrected visual acuity (logMAR) in controls and eyes treated with 4 mg intravitreal triamcinolone at five time intervals.
Figure 2
Figure 2
Mean central macular thickness in controls and eyes treated with 4 mg intravitreal triamcinolone at three time intervals.
See this image and copyright information in PMC

References

    1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133–141. discussion 141–143. - PMC - PubMed
    1. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996;114:1243–1247. - PubMed
    1. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271–282. - PubMed
    1. Oh JY, Seo JH, Ahn JK, Heo JW, Chung H. Early versus late intravitreal triamcinolone acetonide for macular edema associated with branch retinal vein occlusion. Korean J Ophthalmol. 2007;21:18–20. - PMC - PubMed
    1. Lin JM, Chiu YT, Hung PT, Tsai YY. Early treatment of severe cystoid macular edema in central retinal vein occlusion with posterior subtenon triamcinolone acetonide. Retina. 2007;27:180–189. - PubMed

LinkOut - more resources